MEDIMMUNE U.K. LIMITED - Profile & Financials

Accounts Submitted 7 Aug 2025

Confirmation Statement Submitted 23 Jun 2025

Net assets £71.07M £6.93M 2024 year on year

Total assets £103.00M £2.18M 2024 year on year

Total Liabilities £31.94M £4.75M 2024 year on year

Charges 2

2 outstanding

AI Analysis

Analyze director networks, ownership patterns, and company connections

CompanyTrack AI can make mistakes. Check important info.

Contact & Details

Contact

Update Details

Registered Address

Plot 6 Renaissance Way Boulevard Industry Park Speke Liverpool L24 9JW

Office (Macclesfield)

Alderley Park, Alderley House, Park Estate, Macclesfield SK10 4TF

Telephone

0800 783 0033

support@suspected-severe-asthma.co.uk

Website

astrazeneca.co.uk

Credit Report

Discover MEDIMMUNE U.K. LIMITED's Credit Score, limit, and payment likelihood.

Mutual Companies

See All Mutual Companies

Financials

Period 1 Jan → 31 Dec 2024

Type Total Exemption Full

Next accounts 31 December 2025

Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2014–2024)

Cash in Bank

N/A

Net Assets

£71.07M

Increased by £6.93M (+11%)

Total Liabilities

£31.94M

Decreased by £4.75M (-13%)

Turnover

£74.82M

Decreased by £3.63M (-5%)

Employees

330

Increased by 3 (+1%)

Debt Ratio

31%

Decreased by 5 (-14%)

Financial History

Revenue, profit, EBITDA and key financial figures

	2024 Dec Year End	2023 Dec Year End
P&L
Revenue	£142.3M	£128.7M
Gross Profit	£48.2M	£43.1M
Operating Profit	£22.4M	£19.8M
Net Profit	£18.1M	£15.9M
EBITDA	£31.5M	£28.2M
Assets
Cash	£24.7M	£21.3M
Total Assets	£89.4M	£82.1M
Liabilities
Total Liabilities	£45.2M	£41.8M
Key Metrics
Employees	1,247	1,156

Latest Revenue

£142.3M

Latest EBITDA

£31.5M

Cash Position

£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Officers

4 active 23 resigned

Show resigned officers

						Status
Camilla Jane Johnstone	Secretary	Unknown	Unknown	—	16 Sept 2019	Active
Hannah Victoria Tattersall	Director	British	England	38	1 May 2025	Active
Iain Alistair Collins	Director	British	United Kingdom	55	31 May 2017	Active
Matthew Shaun Bowden	Director	British	England	48	27 Feb 2019	Active

Shareholders

Shareholders (2)


Astrazeneca Uk Limited	100.0%	19,756,961	Ordinary	19 Jun 2017
Medimmune, Llc	0.0%	0	Ordinary	19 Jun 2017

Persons with Significant Control

Persons with Significant Control (1)

1 Active 1 Ceased

Astrazeneca Uk Limited

United Kingdom

Active

Notified 1 Jan 2017

Nature of Control

Ownership Of Shares 75 To 100 Percent
Voting Rights 75 To 100 Percent
Right To Appoint And Remove Directors

Astrazeneca Treasury Limited

Ceased 1 Jan 2017

Ceased

See All Controllers

Group Structure

ASTRAZENECA UK LIMITED united kingdom shares 75 to 100 percent, voting rights 75 to 100 percent, appoint/remove directors

ASTRAZENECA INTERMEDIATE HOLDINGS LIMITED united kingdom shares 75 to 100 percent, voting rights 75 to 100 percent, appoint/remove directors

ASTRAZENECA PLC united kingdom

MEDIMMUNE U.K. LIMITED Current Company

Charges

2 outstanding

Documents

Company Filings

Date	Category	Description	Document
7 Aug 2025	Accounts	Annual accounts made up to 2024-12-31	View(28 pages)
23 Jun 2025	Confirmation Statement	Confirmation statement made on 2025-06-16 with no updates	View(3 pages)
2 May 2025	Officers	Appointment of Hannah Victoria Tattersall as director on 2025-05-01	View(2 pages)
1 May 2025	Officers	Termination of Adrian Charles Noel Kemp as director on 2025-05-01	View(1 page)
27 Nov 2024	Incorporation	Memorandum Articles	View(34 pages)